Back to Search
MICHAEL MEUTH, MD
MD
Interventional Cardiology Physician
NPI: 1982608956IndividualAccepts Medicare
Specialties, Licenses & Credentials
Interventional Cardiology PhysicianPrimary
Internal Medicine — Interventional Cardiology
Code: 207RI0011X
159159(MA)
CMS Specialties
PrimaryINTERVENTIONAL CARDIOLOGY
Additional
CARDIOVASCULAR DISEASE (CARDIOLOGY)INTERVENTIONAL PAIN MANAGEMENT
Education
GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE
Class of 1995
Research & Publications (20)
ATR and Chk1 suppress a caspase-3-dependent apoptotic response following DNA replication stress.
PMID 19119425·PLoS Genet·2009
8-other
FGFR3 mutations indicate better survival in invasive upper urinary tract and bladder tumours.
PMID 18584939·Eur Urol·2009
8-other
A mutant allele of MRE11 found in mismatch repair-deficient tumor cells suppresses the cellular response to DNA replication fork stress in a dominant negative manner.
PMID 18256278·Mol Biol Cell·2008
8-other
Apoptosis induced by replication inhibitors in Chk1-depleted cells is dependent upon the helicase cofactor Cdc45.
PMID 18239674·Cell Death Differ·2008
7-preclinical
Thymidine selectively enhances growth suppressive effects of camptothecin/irinotecan in MSI+ cells and tumors containing a mutation of MRE11.
PMID 18765539·Clin Cancer Res·2008
7-preclinical
A comparison of the performance of microsatellite and methylation urine analysis for predicting the recurrence of urothelial cell carcinoma, and definition of a set of markers by Bayesian network analysis.
PMID 18325051·BJU Int·2008
4-observational
Promoter hypermethylation in circulating blood cells identifies prostate cancer progression.
PMID 17960617·Int J Cancer·2008
4-observational
Promoter hypermethylation identifies progression risk in bladder cancer.
PMID 17404085·Clin Cancer Res·2007
8-other
Molecular detection of localized prostate cancer using quantitative methylation-specific PCR on urinary cells obtained following prostate massage.
PMID 17363525·Clin Cancer Res·2007
4-observational
Methylational urinalysis: a prospective study of bladder cancer patients and age stratified benign controls.
PMID 16288222·Oncogene·2006
8-other
[Mutation of the FGFR3 oncogene is an independent and favorable prognostic factor for tumor-specific survival in patients with urothelial carcinoma of the upper urinary tract].
PMID 17867603·Verh Dtsch Ges Pathol·2006
8-other
Multifocal urothelial cancers with the mutator phenotype are of monoclonal origin and require panurothelial treatment for tumor clearance.
PMID 16697867·J Urol·2006
8-other
Evidence for the early onset of aberrant promoter methylation in urothelial carcinoma.
PMID 16639696·J Pathol·2006
8-other
Chk1 and p21 cooperate to prevent apoptosis during DNA replication fork stress.
PMID 16280359·Mol Biol Cell·2006
8-other
Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase.
PMID 15829966·Nature·2005
7-preclinical
[Promoter methylation and microsatellite mutation reveals the clonal relationship of multiple urothelial carcinomas with mutator phenotype].
PMID 18035696·Verh Dtsch Ges Pathol·2005
8-other
Promoter hypermethylation is associated with tumor location, stage, and subsequent progression in transitional cell carcinoma.
PMID 15753461·J Clin Oncol·2005
8-other
A tumour-derived mutant allele of XRCC2 preferentially suppresses homologous recombination at DNA replication forks.
PMID 14645207·Hum Mol Genet·2004
8-other
Association of a common variant of the CASP8 gene with reduced risk of breast cancer.
PMID 15601643·J Natl Cancer Inst·2004
8-other
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 1565 NORTH MAIN STREET, SUITE 306
FALL RIVER, MA 02720 - Phone
- (508) 973-9500
Quick Facts
- NPI
- 1982608956
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 1
- Locations
- 1
- Years in Practice
- 31
- Publications
- 20
Are you this provider?
Claim Your Profile